Ness-Ziona, Israel December 4th , 2013 — Medicortex USA Ltd. CEO will participate in the 22nd ISFN

Traumatic Brain Injury (TBI) is a frequent neurological condition, representing a worldwide economic burden with rapidly growing incidence. TBI is difficult to diagnose because of the many different performances in each individual following the initial trauma and subsequent late stage clinical signs, which appear following the primary TBI incident. TBI involves the injured patient, his/her immediate family, the social environment, as well as the health facilities and social services. In addition, as yet no drug is available to address the progression of the secondary injury to the brain upon TBI.

Dr. Adrian Harel, Medicortex’s owner and CEO, stated: "I will present the developing plan of our new drug candidates, which are aimed to moderate the pathology of TBI. The company has designed three chemically verified proprietary NCE’s, each with lipophilic properties for crossing the brain-blood-barrier, and possessing at least two neuroprotective functions, such as free metal ion binding, anti-oxidation, anti-inflammation, and/or anti-bacterial. I will present the research plan for the initial studies assessing the biological activity and lack of toxicity of our pipeline compounds."

About TBI
TBI is a complex condition, in which various different biochemical pathways are impaired, thereby causing a multi-system neurodegenerative disorder. Given the complexities of TBI, current drugs in clinical trials have failed to reach their endpoints, as they are aimed to one single/specific target.

It is estimated that the TBI therapeutics market will grow at 3.8% annually for the next 4 years, reaching $2 billion by 2017. According to the National Centers for Disease Control (CDC), there are approximately 1.7 million TBI incidents in the US each year. Of these, an estimated 5% - 15% suffer from moderate to severe permanent brain impairment. Secondary brain injury in patients with severe or mild TBI occurs as a result of increased permeability of the neuronal membrane, followed by an excessive influx of metal ions and circulating free radicals.

This causes a series of protein degradation cascades and oxidation, leading to widespread molecular damage and neuronal cell death. The outcomes of this chain of events include permanent disability and even death.

About Medicortex
Medicortex is an innovative, proof-of-concept biotechnology company developing breakthrough drug agents for the treatment of TBI, Spinal Cord Injury, stroke, toxic nerve agent exposure, and other acute neurodegenerative conditions. The company's initial focus is on preventing secondary brain injury in TBI, a complex process caused by the multitude biochemical changes upon the primary injury. Medicortex's unique neuroprotective strategy is to introduce a multi-functional compound that addresses several biochemical and physiological pathways simultaneously.

Medicortex is a privately held company founded in 2010 by Dr. Adrian Harel, an experienced neurobiologist with a track record in business management and in the leadership of early-stage drug discovery companies. His collaboration with renowned experts in medicinal chemistry promises the establishment of a successful pipeline of innovative molecules for the treatment of acute neurodegenerative disorders.

A new and updated web site of the company can be evaluated: www.medicortex.com

Disclaimer:
This news release contains forward-looking content and concepts, involving risks and uncertainties. Actual results may differ from anticipated results communicate in this news release.
Contact:
Dr. Adrian Harel, CEO
e-mail: hareladrian@yahoo.com
www.medicortex.com